Swiss spin-out raises €9.5 million in Series A

Aleva Neurotherapeutics SA of Lausanne, Switzerland has raised €9.5 million in a Series A round to support development of its implant technology for deep brain stimulation which would complement drug therapy for major neurological disorders.